Greenwich Lifesciences

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, New York--(Newsfile Corp. - October 20, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/greenwich-lifesciences-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI

Biomea Fusion Inc

Volt Information Sciences, Inc.

Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subscribe to Tom's mailing list here.

The Moonshot Investor: The Insider Track Strategy

Studies have found that insiders outperform the market by 6-15%. Over a long period, that's an incredible achievement and worth understanding.

A Controversial Moonshot Stock Just Got a Lot More Interesting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Set to Join Russell 2000® Index

Greenwich LifeSciences Set to Join Russell 2000® Index

Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?

1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

The drop came despite the clinical-stage biotech announcing good news over the weekend.

Why Greenwich LifeSciences Stock Tanked Today

STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

The company reported positive data for its cancer immunotherapy candidate GP2.

Why Greenwich LifeSciences Stock Is Rising Today

PriceSmart

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by more than 15% after the company reported a robust immune response from its Phase 2b data supporting the GP2 clinical outcome of 0% metastatic breast cancer recurrences over five years of follow-up. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of immunotherapy to prevent breast cancer recurrences in patients.

What's Going On With GLSI Stock And PSMT Stock Today?

The stock price of Greenwich LifeSciences (NASDAQ: GLSI) increased by over 20% pre-market. This is why it happened.

Greenwich LifeSciences Stock Price Increased Over 20% Pre-Market: Why It Happened

Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting.  The company plans to publish the poster, the abstract, and an audio recording tomorrow in a joint press release.

Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-up

STAFFORD, Texas--(BUSINESS WIRE)--GLSI Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years Follow-up

Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up

Greenwich LifeSciences is advancing cancer treatments with life-changing potential, and recent developments should boost GLSI stock's value. The post Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy appeared first on InvestorPlace.

Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy

On December 8, 2020, Greenwich LifeSciences (NASDAQ: GLSI) share price closed at $5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio Breast Cancer Symposium conference on December 9, which showed 0% breast cancer recurrences over 5 years of follow-up.

Greenwich LifeSciences Could See Another Spike in Stock in Early April

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly 3,000% in a single day in December after a Phase 2b trial suggested the therapy can reduce breast cancer recurrence rates down to zero.

News for Greenwich Lifesciences Stock (GLSI)